Abstract WP075: Antithrombotic Management Before Carotid Endarterectomy in Recently Symptomatic Patients

BACKGROUND: There is limited evidence and few recommendations in best practice guidelines regarding the optimal antithrombotic strategy prior to carotid endarterectomy (CEA) in patients with recently symptomatic carotid disease. We examined current practices at a large Canadian tertiary stroke center. METHODS: Patients undergoing CEA for symptomatic carotid stenosis between 2018–2022 were identified through hospital administrative data using procedural codes. Chart review was performed to confirm transient ischemic attack (TIA) or ischemic stroke within 2 weeks of surgery. We compared patient demographics, comorbidities, recurrent ischemic and bleeding events, and post-surgical complications across pre-procedure antithrombotic strategies, applying Bonferroni correction for multiple testing. RESULTS: We identified 217 patients who underwent CEA within 2 weeks of symptom onset due to carotid stenosis >50%. Nearly all (98.2%) were on antithrombotic therapy prior to surgery: 21% on single antiplatelet therapy, 15% on dual antiplatelet therapy, 2.3% on anticoagulation alone, and 59% on combined anticoagulation and antiplatelet therapy. There were no significant differences in age, sex, time from symptom onset to admission, or degree of stenosis across treatment groups. Atrial fibrillation was more frequent among patients on anticoagulation (alone or in combination) compared with those on antiplatelets alone. No periprocedural deaths occurred. The overall rate of recurrent cerebral ischemic events before CEA was 5.5%, bleeding complications (including pre- and post-procedure) occurred in 1.8%, perioperative myocardial infarction in 0.5%, and periprocedural stroke in 3.7%, with no significant differences between antithrombotic strategies (Table 1). CONCLUSIONS: We observed substantial variation in antithrombotic strategies prior to CEA, without significant differences in rates of recurrent ischemic events, bleeding, or perioperative complications.

Authors

Institutions

Publication Details

Journal
Stroke
Published
2026-01-29
DOI
https://doi.org/10.1161/str.57.suppl_1.wp075
Primary Topic
Cerebrovascular and Carotid Artery Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract WP075: Antithrombotic Management Before Carotid Endarterectomy in Recently Symptomatic Patients

Lily W. Zhou, Shaheer Lakhani
Stroke
Cerebrovascular and Carotid Artery Diseases
article

Abstract WP075: Antithrombotic Management Before Carotid Endarterectomy in Recently Symptomatic Patients

Lily W. Zhou, Shaheer Lakhani
article en

Abstract

BACKGROUND: There is limited evidence and few recommendations in best practice guidelines regarding the optimal antithrombotic strategy prior to carotid endarterectomy (CEA) in patients with recently symptomatic carotid disease. We examined current practices at a large Canadian tertiary stroke center. METHODS: Patients undergoing CEA for symptomatic carotid stenosis between 2018–2022 were identified through hospital administrative data using procedural codes. Chart review was performed to confirm transient ischemic attack (TIA) or ischemic stroke within 2 weeks of surgery. We compared patient demographics, comorbidities, recurrent ischemic and bleeding events, and post-surgical complications across pre-procedure antithrombotic strategies, applying Bonferroni correction for multiple testing. RESULTS: We identified 217 patients who underwent CEA within 2 weeks of symptom onset due to carotid stenosis >50%. Nearly all (98.2%) were on antithrombotic therapy prior to surgery: 21% on single antiplatelet therapy, 15% on dual antiplatelet therapy, 2.3% on anticoagulation alone, and 59% on combined anticoagulation and antiplatelet therapy. There were no significant differences in age, sex, time from symptom onset to admission, or degree of stenosis across treatment groups. Atrial fibrillation was more frequent among patients on anticoagulation (alone or in combination) compared with those on antiplatelets alone. No periprocedural deaths occurred. The overall rate of recurrent cerebral ischemic events before CEA was 5.5%, bleeding complications (including pre- and post-procedure) occurred in 1.8%, perioperative myocardial infarction in 0.5%, and periprocedural stroke in 3.7%, with no significant differences between antithrombotic strategies (Table 1). CONCLUSIONS: We observed substantial variation in antithrombotic strategies prior to CEA, without significant differences in rates of recurrent ischemic events, bleeding, or perioperative complications.

StrokeVol. 57(Suppl_1)
University of British Columbia (CA)
Good health and well-being
Openalex Percentile: Top 74%
Cerebrovascular and Carotid Artery Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Abstract WP075: Antithrombotic Management Before Carotid Endarterectomy in Recently Symptomatic Patients — Lily W. Zhou, Shaheer Lakhani · Stroke (2026) | TGRS Research Map | TGRS